PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H. Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H. Won, Sasinya N. Scott, A. Rose Brannon, Catherine O'Reilly, Justyna Sadowska, Jacklyn Casanova, Angela Yannes, Jaclyn F. Hechtman, Jinjuan Yao, Wei Song, Dara S. Ross, Alifya Oultache, Snjezana Dogan, Laetitia Borsu, Meera Hameed, Khedoudja Nafa, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology The Journal of Molecular Diagnostics. ,vol. 17, pp. 251- 264 ,(2015) , 10.1016/J.JMOLDX.2014.12.006

Olivier Coqueret, New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends in Cell Biology. ,vol. 13, pp. 65- 70 ,(2003) , 10.1016/S0962-8924(02)00043-0

Stacy Blain, Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle. ,vol. 7, pp. 892- 898 ,(2008) , 10.4161/CC.7.7.5637

Gail T. McDonald, Richard Sullivan, Geneviève C. Paré, Charles H. Graham, Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Experimental Cell Research. ,vol. 316, pp. 3197- 3206 ,(2010) , 10.1016/J.YEXCR.2010.08.007

John J. Tentler, Aik Choon Tan, Colin D. Weekes, Antonio Jimeno, Stephen Leong, Todd M. Pitts, John J. Arcaroli, Wells A. Messersmith, S. Gail Eckhardt, Patient-derived tumour xenografts as models for oncology drug development Nature Reviews Clinical Oncology. ,vol. 9, pp. 338- 350 ,(2012) , 10.1038/NRCLINONC.2012.61

L Connell-Crowley, E Swindell, J W Harper, S J Elledge, K Keyomarsi, B Dynlacht, L H Tsai, P Zhang, S Dobrowolski, C Bai, Inhibition of cyclin-dependent kinases by p21. Molecular Biology of the Cell. ,vol. 6, pp. 387- 400 ,(1995) , 10.1091/MBC.6.4.387

J. J. Wallin, J. Guan, W. W. Prior, K. A. Edgar, R. Kassees, D. Sampath, M. Belvin, L. S. Friedman, Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. Science Translational Medicine. ,vol. 2, ,(2010) , 10.1126/SCITRANSLMED.3000630

Kristi McIntyre, Joyce O’Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, Linda T. Vahdat, Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer Breast Cancer Research and Treatment. ,vol. 146, pp. 321- 328 ,(2014) , 10.1007/S10549-014-2923-9

Jordi Rodon, Rodrigo Dienstmann, Violeta Serra, Josep Tabernero, None, Development of PI3K inhibitors: lessons learned from early clinical trials Nature Reviews Clinical Oncology. ,vol. 10, pp. 143- 153 ,(2013) , 10.1038/NRCLINONC.2013.10

Ji-Liang Li, Adrian L. Harris, Notch signaling from tumor cells: A new mechanism of angiogenesis Cancer Cell. ,vol. 8, pp. 1- 3 ,(2005) , 10.1016/J.CCR.2005.06.013